These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 22851709)

  • 1. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.
    Zhang T; Wu MR; Sentman CL
    J Immunol; 2012 Sep; 189(5):2290-9. PubMed ID: 22851709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.
    Ponath V; Hoffmann N; Bergmann L; Mäder C; Alashkar Alhamwe B; Preußer C; Pogge von Strandmann E
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.
    Xu X; Li Y; Gauthier L; Chen Q; Vivier E; Mariuzza RA
    Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):697-701. PubMed ID: 26057798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
    Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
    J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity.
    Wu MR; Zhang T; DeMars LR; Sentman CL
    Gene Ther; 2015 Aug; 22(8):675-84. PubMed ID: 25830550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
    Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
    J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.
    Semeraro M; Rusakiewicz S; Minard-Colin V; Delahaye NF; Enot D; Vély F; Marabelle A; Papoular B; Piperoglou C; Ponzoni M; Perri P; Tchirkov A; Matta J; Lapierre V; Shekarian T; Valsesia-Wittmann S; Commo F; Prada N; Poirier-Colame V; Bressac B; Cotteret S; Brugieres L; Farace F; Chaput N; Kroemer G; Valteau-Couanet D; Zitvogel L
    Sci Transl Med; 2015 Apr; 7(283):283ra55. PubMed ID: 25877893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
    Fiegler N; Textor S; Arnold A; Rölle A; Oehme I; Breuhahn K; Moldenhauer G; Witzens-Harig M; Cerwenka A
    Blood; 2013 Aug; 122(5):684-93. PubMed ID: 23801635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30.
    Xu X; Narni-Mancinelli E; Cantoni C; Li Y; Guia S; Gauthier L; Chen Q; Moretta A; Vély F; Eisenstein E; Rangarajan S; Vivier E; Mariuzza RA
    J Mol Biol; 2016 Nov; 428(22):4457-4466. PubMed ID: 27663271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6.
    Li Y; Wang Q; Mariuzza RA
    J Exp Med; 2011 Apr; 208(4):703-14. PubMed ID: 21422170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30.
    Butler SE; Brog RA; Chang CH; Sentman CL; Huang YH; Ackerman ME
    Cancer Immunol Immunother; 2022 Jan; 71(1):165-176. PubMed ID: 34046711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure.
    Zou Y; Bao J; Pan X; Lu Y; Liao S; Wang X; Wang G; Lin D
    PLoS One; 2015; 10(8):e0134568. PubMed ID: 26241657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
    Zhang T; Lemoi BA; Sentman CL
    Blood; 2005 Sep; 106(5):1544-51. PubMed ID: 15890688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
    Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
    Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.
    Brandt CS; Baratin M; Yi EC; Kennedy J; Gao Z; Fox B; Haldeman B; Ostrander CD; Kaifu T; Chabannon C; Moretta A; West R; Xu W; Vivier E; Levin SD
    J Exp Med; 2009 Jul; 206(7):1495-503. PubMed ID: 19528259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
    Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
    Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
    Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
    Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
    Spear P; Barber A; Rynda-Apple A; Sentman CL
    Immunol Cell Biol; 2013 Jul; 91(6):435-40. PubMed ID: 23628805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.
    Schlecker E; Fiegler N; Arnold A; Altevogt P; Rose-John S; Moldenhauer G; Sucker A; Paschen A; von Strandmann EP; Textor S; Cerwenka A
    Cancer Res; 2014 Jul; 74(13):3429-40. PubMed ID: 24780758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction.
    Müller T; Schlahsa L; Zhang HJ; Skaik Y; Eiz-Vesper B; Immenschuh S; Blasczyk R; Figueiredo C
    J Biol Regul Homeost Agents; 2014; 28(2):183-93. PubMed ID: 25001651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.